This month, MEGIN is delighted to be among the delegate of leading UK HealthTech innovators heading to Tennessee to strengthen trade links and showcase their products and services to the US market.
The visit marks the second major US trade mission organised this year by the Association of British HealthTech Industries (ABHI) as part of its flagship US Accelerator programme.
The missions – exclusive to members of the ABHI US Accelerator – aim to provide participants with access to senior leaders, clinicians and procurement teams from world-class hospital systems in the US, supporting them in engaging the right stakeholders and exploring key markets.
Along with a cohort of over 20 companies, MEGIN will be showcasing our leading MEG technology.
In the US, Tennessee is renowned as a life sciences powerhouse – and ranks second in the nation in exports of medical equipment and supplies, with a total of $4 billion in 2020.
ABHI’s week-long mission will introduce members to the leaders from across this dynamic ecosystem, including hospital systems, accelerators, business chambers and professional service companies.
The visit will provide a prime opportunity for members to explore the strengths of two its biggest cities, Memphis and Nashville – home to world-renowned research institutions and a cluster of innovative companies. Ideal for UK HealthTech companies that are keen to develop and strengthen trade partnerships across the state, the mission aims to generate further demand for UK-developed products.
“MEGIN is delighted to be among the UK HealthTech pioneers joining the ABHI trade mission to Tennessee. The state is currently home to one MEGIN device, and we hope to continue expansion in the region. We aim to build greater MEG awareness on this trip, and highlight how our non-invasive technology can support clinical outcomes in epilepsy through data allowing for more informed decision-making, as well as MEG’s utilization in research. We look forward to meeting with clinical leaders, exploring the opportunities for collaboration within Tennessee’s flourishing healthcare and life sciences ecosystem, and showcasing what we have to offer,” said Shawn Walls, Senior Training and Application Specialist, and delegate from MEGIN on the trade mission.
Centred in Texas, the ABHI US Accelerator is delivered in partnership with the Dell Medical School, one of the United States’ most pioneering academic institutions, based at the University of Texas, in Austin. Using the state as a springboard to other key states, the programme offers nationwide support, drawing on the relationships and connections ABHI has cultivated across the US.
Central to the 12-month programme is ABHI’s calendar of trade missions, which take place throughout the year, taking members to key states across the US, enabling them to explore new markets, minimise risk, meet new customers and gain valuable market insight.
The upcoming trade mission will allow participants to explore Tennessee’s burgeoning healthcare and technology sector. The region is home to world-class systems and hospitals, supported by world-class research capabilities, and is renowned for housing a greater employment concentration for the healthcare and medical devices sector compared to both the Southeast and the US.
In addition, it is the birthplace of HCA – the world’s largest private hospital group – offering a vast number of opportunities for UK HealthTech innovators and entrepreneurs looking to tap into this flourishing ecosystem.
The cohort of companies taking part in the visit will be showcasing a range of UK HealthTech products and solutions. Throughout the week, meetings will take place with senior leadership from hospital systems, group purchasing organizations (GPOs), distributors, investors and procurement teams across Nashville and Memphis. The mission will incorporate a series of group meetings, networking events, working groups and introductions to a range of supporting organisations, including the Nashville Area Chamber of Commerce, Greater Nashville Technology Council, as well as the senior leadership teams from HCA Healthcare and Ascension Saint Thomas Hospital.
Throughout the rest of the year, participants of this year’s ABHI US Accelerator will also take part in missions to other key states, taking them as far wide as Minnesota, Florida and Boston, where this year’s MedTech Conference is being held.
Paul Benton, Managing Director, International, ABHI commented: “The healthcare industry in Tennessee is a juggernaut that deserves a greater share of voice when compared to other parts of the country. We are looking forward to bringing back some of the UK’s leading healthcare innovators and clinicians to this vibrant state in July. Tennessee boasts a significant presence from world-leading systems and hospitals, and the scale of this health economy has driven an influx of entrepreneurs and investment in recent years. Our visit will accordingly give our members a chance to explore the ample opportunities for collaboration and partnership in the region and showcase what the UK’s HealthTech community has to offer.”
For more information, visit: https://www.abhi.org.uk/international/abhi-us-accelerator/
ABHI is the UK’s leading industry association for health technology (HealthTech).
ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is the largest employer in the broader Life Sciences sector, employing 138,100 people in 4,140 companies, with a combined turnover of £27.6bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 320 members account for approximately 80% of the sector by value.
MEGIN is a neuroscience technology company based in Helsinki, Finland. The company is focused on developing innovative solutions for functional brain mapping for the presurgical evaluation of epilepsy, brain tumors or other lesions of the brain. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology. The TRIUX™ neo provides a non-invasive, real-time view of patient-specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information currently available on the market.
© 2022 MEGIN – TRIUX™ neo is available for sale in EU and USA markets. In other geographical areas, contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively locate regions of epileptic activity within the brain and, in conjunction with other diagnostic data, in neurosurgical planning. All other applications are research in nature. Please contact for data references and any further information.